CVS Q1 2025 Earnings Beat, ACA Exit Detailed

CVS Health reported first-quarter 2025 earnings above expectations, with adjusted earnings per share of $2.25 and revenue reaching $94.6 billion. The company raised its full-year adjusted EPS guidance to a range of $6.00–$6.20, citing improvements in Medicare Advantage performance, better star ratings, and strong results across multiple business segments. CVS also announced that its Aetna unit will exit the Affordable Care Act (ACA) individual exchange business next year due to persistent losses. Shares of CVS surged more than 9% in premarket trading, rebounding from a challenging previous year. Additionally, CVS finalized a deal to prioritize Novo Nordisk’s weight-loss drug Wegovy for clients of its Caremark pharmacy-benefit manager. The company’s operational efficiency and financial health were emphasized as drivers for its optimistic outlook.